Onkologie. 2022:16(3):127-129 | DOI: 10.36290/xon.2022.025

Immunotherapy for patients with pancreatic adenocarcinoma

Stanislav John
Klinika onkologie a radioterapie, FN Hradec Králové

Pancreatic ductal adenocarcinoma has been long count to one of the most severe diagnosis in solid oncology. Increasing incidence and persistently high mortality lead to intensive research into this highly malignant disease. Chemotherapy, in specific cases supplemented with radiotherapy, is still the most effective treatment modality. The use of targeted therapy is also limited. As with other cancers, great hopes are placed in the renaissance of immunotherapy. The following article aims to provide a brief summary of the knowledge so far gained on the treatment of patients with PDAC by modulating the immune system and outlining new possibilities and current trends.

Keywords: pancreatic adenocarcinoma, immunotherapy, interferon, GVAX, PD-L1.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
John S. Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie. 2022;16(3):127-129. doi: 10.36290/xon.2022.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70(1):7-30. Go to original source... Go to PubMed...
    2. Strobel O, et al. Optimizing the outcomes of pancreatic can­cer surgery. Nat Rev Clin Oncol. 2019;16(1):11-26. Go to original source... Go to PubMed...
    3. Tempero MA, NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019;17(5.5):603-605. Go to original source... Go to PubMed...
    4. Burris HA, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413. Go to original source... Go to PubMed...
    5. Ducreux M, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v56-68. Go to original source... Go to PubMed...
    6. Vogel A, et al. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer. 2016;16(1):817. Go to original source... Go to PubMed...
    7. Vienot A, et al. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol. 2020;12(3):332-346. Go to original source... Go to PubMed...
    8. Wang S, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249. Go to original source... Go to PubMed...
    9. Golan T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327. Go to original source... Go to PubMed...
    10. Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966. Go to original source... Go to PubMed...
    11. Weniger M, Honselmann KC, Liss AS. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. Cancers (Basel). 2018;10(9). Go to original source... Go to PubMed...
    12. Schnittert J, Bansal R, Prakash J. Targeting Pancreatic Stellate Cells in Cancer. Trends Cancer. 2019;5(2):128-142. Go to original source... Go to PubMed...
    13. Van Cutsem E, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38(27):3185-3194. Go to original source... Go to PubMed...
    14. Blaauboer A, et al. Type I interferons in pancreatic cancer and development of new therapeutic approaches. Crit Rev Oncol Hematol. 2021;159:103204. Go to original source... Go to PubMed...
    15. Woo SR, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830-842. Go to original source... Go to PubMed...
    16. Duewell P, et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ. 2014;21(12):1825-1837. Go to original source...
    17. Lutz E, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253(2):328-335. Go to original source... Go to PubMed...
    18. Laheru D, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14(5):1455-1463. Go to original source... Go to PubMed...
    19. Le DT, et al. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019;25(18):5493-5502. Go to original source... Go to PubMed...
    20. Weden S, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011;128(5):1120-1128. Go to original source... Go to PubMed...
    21. Miyazawa M, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int J Cancer. 2017;140(4):973-982. Go to original source... Go to PubMed...
    22. Zhou S, et al. Clinical and Immunological Effects of p53-Targeting Vaccines. Front Cell Dev Biol. 2021;9:762796. Go to original source... Go to PubMed...
    23. Syn NL, et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18(12):e731-e741. Go to original source... Go to PubMed...
    24. Royal RE, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828-833. Go to original source... Go to PubMed...
    25. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465. Go to original source... Go to PubMed...
    26. Marabelle A, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. Go to original source... Go to PubMed...
    27. Hu ZI, et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res. 2018;24(6):1326-1336. Go to original source... Go to PubMed...
    28. Ahmad-Nielsen SA, et al. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Pathol Res Pract. 2020;216(6):152985. Go to original source... Go to PubMed...
    29. Zheng L. PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst. 2017;109(6). Go to original source... Go to PubMed...
    30. Terrero G, et al. Exceptional responses to ipilimumab/nivolumab (ipi/nivo) in patients (pts) with refractory pancreatic ductal adenocarcinoma (PDAC) and germline BRCA or RAD51 mutations. Journal of Clinical Oncology. 2020;38(4_suppl):754-754. Go to original source...
    31. Zhu X, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2021;22(8):1093-1102. Go to original source... Go to PubMed...
    32. Ngwa W, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313-322. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.